Skip to main content
Publications
Wooddell M, Goss DS, Hollis KA, Millar K, Silvia S, Siegel P, Bennett ME, Wolf RA, Hogue SL, White MV. Epinephrine administration for cases of anaphylaxis in a US school setting: results from the EpiPen4Schools survey. Poster presented at the 2015 AAAAI Annual Meeting; February 20, 2015. Houston, TX. [abstract] J Allergy Clin Immunol. 2015 Feb; 135(2):AB212.
Gascon M, Casas M, Morales E, Valvi D, Ballesteros-Gomez A, Luque N, Rubio S, Monfort N, Ventura R, Martinez D, Sunyer J, Vrijheid M. Prenatal exposure to bisphenol A and phthalates and childhood respiratory tract infections and allergy. J Allergy Clin Immunol. 2015 Feb;135(2):370-8. doi: 10.1016/j.jaci.2014.09.030
White MV, Goss D, Hollis K, Millar K, Silvia S, Siegel P, Bennett ME, Wolf RA, Wooddell M, Hogue S. EpiPen4Schools® survey: characteristics of anaphylaxis and common triggers. Poster presented at the 2015 AAAAI Annual Meeting; February 15, 2015. Houston, TX. [abstract] J Allergy Clin Immunol. 2015 Feb; 135(Suppl 2):AB212.
Hogue SL, Bennett ME, Goss DS, Hollis KA, Millar K, Silvia S, Siegel P, Wolf RA, Wooddell M, White MV. Occurrence of anaphylaxis by school grade level and staff training: findings from the EpiPen4Schools survey. Poster presented at the 2015 AAAAI Annual Meeting; February 23, 2015. Houston, TX. [abstract] J Allergy Clin Immunol. 2015; 135(2):AB212.
White MV, Goss DS, Hollis KA, Millar K, Silvia S, Siegel P, Bennett ME, Wolf RA, Wooddell M, Hogue SL. EpiPen4Schools survey: characteristics of anaphylaxis and common triggers. Poster presented at the 2015 AAAAI Annual Meeting; February 2015. Houston, TX. [abstract] J Allergy Clin Immunol. 2015; 135:AB212.
Alonso-Espinaco V, Marmol M, Alonso V, Escudero P, Horndler C, Ortego J, Gallego R, Garcia-Albeniz X, Jares P, Cuatrecasas M, Jose Lozano J, Castells A, Maurel J. Influence of BRAF mutations and RAC1b/RAC1 mRNA expression ratio on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy. Poster presented at the 2012 ASCO Annual Meeting; June 4, 2012. Chicago, IL. [abstract] J Clin Oncol. 2012 Jun; 30(15_Suppl):3553. doi: 10.1200/jco.2012.30.15_suppl.3553
Kiladjian J-J, Gisslinger H, Passamonti F, Niederwieser D, Mendelson E, Sirulnik LA, Copley-Merriman K, Zhou X, Levy RS, Knoops L, Cervantes F, Barbui T, Barosi G, Vannucchi AM, Harrison CN. Health-related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II study. Poster presented at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO); June 1, 2012. Chicago, IL. [abstract] J Clin Oncol. 2012 Jun 1; 30(15_suppl):6626. doi: 10.1200/jco.2012.30.15_suppl.6626
Choti MA, Mayorga MA, Bobiak S, Kulke M, Yao JC, Bergsland EK, Nakakura EK, Bloomston M, Benson AB, Shah MH, Strosberg JR. Baseline demographics of patients with neuroendocrine tumors presenting to seven national comprehensive cancer network (NCCN) institutions: development of a multi-institutional outcomes database. Poster presented at the 2012 Gastrointestinal Cancers Symposium; February 1, 2012. [abstract] J Clin Oncol. 2012 Feb 1; 30(Number 4_suppl):187. doi: 10.1200/jco.2012.30.4_suppl.187
Maurel J, Garcia-Albeniz X, Mendez Mendez C, Martin-Richard M, Pericay C, Vera R, Aparicio J, Rubini M, Cuatrecasas M. PULSE: An open-label, phase II study assessing double positivity (phospho-insulin-growth factor receptor-1 [pIGF-IR] and matrilysin [MMP7]) expression, as a predictive marker of resistance in previously untreated metastatic colorectal cancer (mCRC) wild-type KRAS patients (pts) treated with panitumumab plus mFOLFOX6—A GEMCAD study. Poster presented at the 2011 ASCO Annual Meeting; June 6, 2011. Chicago, IL. [abstract] J Clin Oncol. 2011 Jun; 29(15_suppl). doi: 10.1200/jco.2011.29.15_suppl.tps164
Nooka AK, DeJoubner NJ, Nabhan C, Zhou X, Taylor M, Byrtek M, Miller TP, Friedberg JW, Zelenetz AD, Link BK, Cerhan JR, Dillon H, Levy D, Hirata J, Flowers C. Examination of the follicular lymphoma international prognostic index (FLIPI) in the national LymphoCare study (NLCS): a US patient cohort treated predominantly in community practices. Poster presented at the American Society of Clinical Oncology Annual Meeting; June 3, 2011. Chicago, IL. [abstract] J Clin Oncol. 2011 May 20; 29(15 Suppl):8036. doi: 10.1200/jco.2011.29.15_suppl.8036
Cella D, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Heyes A, Ochs JS, Wolf MK, Kay AC, Kris MG, Natale RB. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol. 2005 May 1;23(13):2946-54.
Sunyer J, Jarvis D, Pekkanen J, Chinn S, Janson C, Leynaert B, Luczynska C, Garcia-Esteban R, Burney P, Anto JM, European Community Respiratory Health Survey Study Group. Geographic variations in the effect of atopy on asthma in the European Community Respiratory Health Study. J Allergy Clin Immunol. 2004 Nov;114(5):1033-9. doi: 10.1016/j.jaci.2004.05.072
Kavuru M, Melamed J, Gross G, Laforce C, House K, Prillaman B, Baitinger L, Woodring A, Shah T. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2000 Jun;105(6 Pt 1):1108-16. doi: 10.1067/mai.2000.105711.
Selner J, Boltansky H, Chervinsky P, Pearlman D, Pedinoff A, Weinstein S, Wolfe J, Stevens A, Prillaman B, Hamedani A, Harding S, Field E. Low dose inhaled fluticasone propionate administered once daily or twice daily via the Diskus is as safe and effective as beclomethasone diproprionate in steroid naïve patients with asthma. Poster presented at the AAAI/AAI/CIS Joint Meeting; February 21, 1997. [abstract] J Allergy Clin Immunol. 1997 Jan; 99(1 Part 2):1319. doi: 10.1016/S0091-6749(97)81066-4